Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate

Abstract

In this study, a sensitive and reliable method for the quantitation of fenofibric acid in rat plasma was developed and validated using high performance liquid chromatography (HPLC). The plasma samples were prepared by deproteinization, and sildenafil was used as an internal standard. Chromatographic separation was achieved using a reversed-phase (C18) column. The mobile phase, 0.02 M ammonium acetate buffer:acetonitrile (35:65, v/v), was run at a flow rate of 1.0 mL/min, and the column eluent was monitored using an ultraviolet detector at 280 nm at room temperature. The retention times of sildenafil (an internal standard), and fenofibric acid were approximately 5.9 and 7.7 min, respectively. The quantitation limit of fenofibric acid in rat plasma was 0.03 μg/mL. Pharmacokinetic parameters of fenofibric acid was evaluated after oral (at doses of 20 mg/kg) administration of JW322 and fenofibrate in rats. After oral administration (20 mg/kg) of JW322, relative bioavailability was approximately 272.8% compared to fenofibrate.

Key words

JW322 - fenofibric acid - HPLC - bioavailability - rats

• References

• 1 Rosamond W, Flegal K, Furie K. et al. Heart disease and stroke statistics: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: 25-146
• 2 Grundy SM, Cleeman JI, Merz CN. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239
• 3 Fernandez G, Spatz ES, Jablecki C. et al. Statin myopathy: A common dilemma not reflected in clinical trials. Cleveland Clinic Journal of Medicine 2011; 78: 393-403
• 4 Saurav A, Kaushik M, Mohiuddin SM. Fenofibric acid for hyperlipidemia. Expert Opinion on Pharmacotherapy 2012; 13: 717-722
• 5 Staels B, Dallongeville J, Auwerx J. et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093
• 6 Adkins JC, Faulds D. Micronised fenofibrate: A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 1997; 54: 615-633
• 7 Vogt M, Kunath K, Dressman JB. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: Comparison with commercial preparations. European Journal of Pharmaceutics and Biopharmaceutics 2008; 68: 283-288
• 8 Spanier B. Transcriptional and functional regulation of the intestinal peptide transporter PEPT1. Journal of Physiology 2014; 592: 871-879
• 9 Cao F, Gao Y, Wang M. et al. Propylene glycol-linked amino acid/dipeptide diester prodrugs of oleanolic acid for PepT1-mediated transport: synthesis, intestinal permeability, and pharmacokinetics. Molecular Pharmaceutics 2013; 10: 1378-1387
• 10 Bhavesh D, Shah S. Shivprakash. Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: Application to a bioequivalence study. Journal of Chromatography B: Biomedical Sciences and Applications 1996; 687: 437-442
• 11 Masnatta LD, Cuniberti LA, Rey RH. et al. Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography. Biomedical Chromatography 2009; 23: 922-928
• 12 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf
• 13 Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharmaceutical Research 1993; 10: 1009-1095